FURAHA-671, KEYTRUDA, Merck, NSCLC, Pembrolizumab
Neoadjuvant/adjuvant pembrolizumab waxa u ansixisay FDA kansarka sambabada unugyada aan yarayn
Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post-surgical adjuvant treatment f..
Hal qayb oo ka mid ah Array BioPharma Inc, binimetinib, Braftova, encorafenib, Mektovi, Pfizer
Encorafenib oo leh binimetinib waxa ansixisay FDA si loogu daweeyo kansarka sanbabada unug yar-yar oo leh isbeddel BRAF V600E
Maamulka Cuntada iyo Dawooyinka (FDA) waxay ansixiyeen Encorafenib (Braftovi, Array BioPharma Inc., oo ah shirkad hoos timaada Pfizer) iyo binimetinib (Mektovi, Array BioPharma Inc.) bishii Noofambar 2023 sida daawooyinka loo isticmaali karo ...
Arrow tijaabo, Genentech, NSCLC, pralsetinib
Pralsetinib waxa u ansixisay FDA kansarka sambabada unugyada aan yarayn ee leh isku-dhafka hidda-wadaha RET
Agoosto 2023: Pralsetinib (Gavreto, Genentech, Inc.) waxaa si joogta ah u siisay ogolaansho Maamulka Cuntada iyo Dawooyinka ee bukaanada qaangaarka ah ee qaba kansarka sanbabada unugyada yaryar ee RET-ga ah (NSCLC), sida ay go'aamisay FDA.
FDA, Maamulka Cuntada iyo Dawooyinka, KEYTRUDA, Merck, Pembrolizumab, kiimoterabi ku salaysan platinum
Pembrolizumab waxa u ansixisay FDA sidii daawaynta adjuvant ee kansarka sambabada unugyada aan yarayn
Feb 2023: Marxaladda IB (T2a 4 cm), heerka II, ama heerka IIIA kansarka sanbabada unug yar, Maamulka Cuntada iyo Dawooyinka (FDA) waxay ansixiyeen pembrolizumab (Keytruda, Merck) sida daawayn adjuvant ka dib dib-u-soo-saarid iyo kiimiko platinum ku salaysan ..
AstraZeneca Pharmaceuticals, durvalumab, Imjudo, NSCLC, POSEIDON, tremelimumab
Tremelimumab waxa ansixisay FDA oo ay weheliso durvalumab iyo kiimoterabiga platinum-ku-salaysan ee kansarka sambabada ee unugyada aan yarayn.
Noofambar 2022: Isku darka tremelimumab (Imjudo, AstraZeneca Pharmaceuticals), durvalumab (Imfinzi, AstraZeneca Pharmaceuticals), iyo kiimoterabiga ku salaysan platinum waxaa ansixiyay Maamulka Cuntada iyo Dawooyinka ee pa..
Libya, NCT03409614, NSCLC, kiimiko ku salaysan platinum, Dawooyinka Regeneron
Cemiplimab-rwlc waxaa ansixisay FDA iyadoo lagu daray kiimoterabiga platinum-ku-saleysan ee kansarka sambabada unugyada aan yareyn
Noofambar 2022: Isku darka cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) iyo kiimiko ku salaysan platinum oo loogu talagalay bukaanada qaangaarka ah ee qaba kansarka sambabada unugyada yaryar ee horumarsan (NSCLC) oo aan lahayn EGFR, ALK, ama ROS1 aan caadi ahayn.
am-trastuzumab deruxtecan-nxki, Daichi Sankyo, Enhertu
Oggolaanshaha degdega ah waxaa siisay FDA fam-trastuzumab deruxtecan-nxki ee HER2-mutant kansarka sanbabada unug yar
Ogosto 2022: Bukaanada qaangaarka ah ee qaba kansarka sambabada unugyada unugyada yaryar ee dheef-shiid kiimikaadka (NSCLC) kuwaas oo burooyinkooda ay leeyihiin isbeddel taasoo keentay kala-guurka mesenchymal-epithelial (MET) exon 14 ka boodi, sida lagu ogaaday baaritaanka FDA-ansixisay, Cuntada.
Capmatinib, NCT02414139, Hal qayb oo ka mid ah Novartis Pharmaceuticals Corp, NSCLC, Tabrecta
Capmatinib waxaa loo oggolaaday kansarka sambabada unugyada aan yarayn ee metastatic
Ogosto 2022: Bukaanada qaangaarka ah ee qaba kansarka sambabada unugyada unugyada yaryar ee dheef-shiid kiimikaadka (NSCLC) kuwaas oo burooyinkooda ay leeyihiin isbeddel taasoo keentay kala-guurka mesenchymal-epithelial (MET) exon 14 ka boodi, sida lagu ogaaday baaritaanka FDA-ansixisay, Cuntada.
BMS, CHEKMATE-816, nivolumab, NSCLC, Cajiib
Neoadjuvant nivolumab iyo platinum-double chemotherapy ayaa loo oggolaaday marxaladda hore ee kansarka sanbabada unug yar
Maarso 2022: Goobta neoadjuvant, FDA waxay ansixisay nivolumab (Opdivo, Bristol-Myers Squibb Company) oo ay weheliso platina-double chemotherapy oo loogu talagalay bukaanada qaangaarka ah ee qaba kansarka sambabada unugyada yaryar ee aan la soo saari karin (NSCLC)
Atezolizumab, Genentech, NSCLC, Tecentriq, Nidaamyada Caafimaadka ee Ventana, VENTANA PD-L1
Atezolizumab waxa u ansixisay FDA sidii daawaynta adjuvant ee kansarka sambabada unugyada aan yarayn
Noofambar 2021: Maamulka Cuntada iyo Dawooyinka ayaa ansixiyay atezolizumab (Tecentriq, Genentech, Inc.) ee daawaynta adjuvant ee bukaanada leh marxaladda II ilaa IIIA kansarka sambabada unugyada aan-yare ahayn (NSCLC) kuwaas oo burooyinkooda ay ka kooban yihiin PD-L1 o.